

Archived File

The file below has been <u>archived</u> for historical reference purposes only. The content and links are no longer maintained and may be outdated. See the <u>OER Public Archive Home Page</u> for more details about archived files.









George Chacko
Center for Scientific Review
National Institutes of Health
Department of Health and Human Services


Asynchronous Electronic Discussion (AED)

- * Web-based Review Method
- * Threaded Message Board
- * Reviewers separated by time and space
- Thoughtful discussions; more time to think and research
- Potentially less confrontational environment

Logistical Advantages

- Reviewers do not have to travel
- Otherwise unavailable reviewers can be recruited
- Transcript of discussions
- * Improved management of conflicts of interest
- * Time-zone advantage- international reviewers

Information Flow



How Does it Work?

- 1. Reviewers submit critiques to IAR
- The meeting occurs on the website and comprises 3 phases
 - Streamline phase
 - Discussion phase
 - Final scoring phase
- 3. Reviewers revise critiques on IAR.

ZRG1 PRAC



Announcements			
	Message	Posted By/ Posted On	
Ø	SRA and the Chair. Typically, this space is used to provide	Chacko, George (NIH/CSR) [E] 11/21/2006 8:58:35 AM	Reply Edit

Post a new comment

A				

Application	Unread Posts	Total Posts	Status	Conflict
1R01DR12345-01 Doe, John	0	3		
1R01DR53422-01A2 Freund. Robert	0	0		
1R21DR756443-01 Bowers, John	0	0		
1R21DR88881-01A1 Panniers, Richard	0	0	Candidate	
2R01DR78654-04 Chacko, George	0	0	Candidate	

Links	▼ * ×
NIH Web Site	
ERA Commons Web Site	
Add new link	
Deadlines	▼
Title	Deadline
Meeting Begins! NEW	11/21/2006 6:00 AM
End Streamlining ! NEW	11/21/2006 1:00 PM
End Discussion / Begin Private Voting NEW	11/22/2006 5:00 PM
Meeting Ends ! NEW	11/23/2006 6:00 AM

Add new item

▼ 🌣 X





Scientific Exploration

Application Documents

Scores - Initial Scoring						
	Reviewer	Start	Current	Private		
*	Amero, Sally	1.1	1.2			
*	Zullo, Steven (NIH/CSR) [E]	1.3	1.4			
*	Gubin, Alexander (NIH/CSR) [E]	1.4	1.3			
*	Klosek, Malgorzata (NIH/CSR) [E]	1.4	1.4			
	Fan, Ping (NIH/CSR) [E]		1.5			
	Shonat, Ross (NIH/CSR) [E]		1.2			
	White, Geoffrey (NIH/CSR) [E]		1.5			

Score

Application Discussion

Message	Posted By/ Posted On	
Subject: SRA's Comments I'm going to ask Reviewer 1 to briefly reconcile her comments with those of the other assigned reviewers so that we can get a discussion going.	Chacko, George (NIH/CSR) [E] 11/21/2006 3:35:23 PM	Reply
Subject: Clinical Centers In terms of accrual, they cite a number of centers and the numbers of patients that they've had, but they really don't justify these numbers; they don't really provide evidence that each of the sites can accrue patients appropriately for this trial. I felt it would've been strengthened by either a more raw justification based on the literature or based on their own work in terms of how this drug may in fact be influencing a colorectal cell-proliferation. And so for that reason, I gave it the score that I did.	Klosek, Malgorzata (NIH/CSR) [E] 11/21/2006 3:27:54 PM	Reply
Subject: Outstanding Application This is an outstanding application that is likely to have considerable impact if the aims are carried out. The investigating team is top-quality and the the approach is carefully thought out. The level of innovation may be modest but the significance of the work is very high which is why I gave it such a good score. I recognize the mild reservations of my colleagues but I feel strongly that they may not affect the overall merit of this application.	Amero, Sally 11/21/2006 3:35:05 PM	Reply
Subject: Scoring Comment, Score: 1.5 As far as the trial goes, I had some major issues there. This is a group that has not worked together in the past they really have no track record for doing a multi-institutional study; I felt they really didn't support the feasibility of quality control.	Fan, Ping (NIH/CSR) [E] 11/21/2006 3:45:17 PM	Reply
Subject: re: the Doe application I agree pretty much with everything Alexander said, but I was less enthusiastic for a few other reasons. First of all, this is clearly a strong group and they've done a lot of pre-clinical work in this area, and I thought that was a major strength of the application. However, as the first reviewer points out, their justification for picking this particular drug, I think was somewhat lacking. And in fact, their own preliminary data in Table 2 where they actually use their drug compared to Solendac in looking in a rat model of ait looks like there's really not much difference between these two groups. So, I thought they needed to really strengthen their rationale for selecting this agent in the first place.	Zullo, Steven (NIH/CSR) [E] 11/21/2006 3:50:03 PM	Reply Edit

Post a new comment

Budget Discussion

Message	Posted By/ Posted On	
	Klosek, Malgorzata (NIH/CSR) [E] 11/21/2006 12:18:35 PM	Reply

Post a new comment

State of the Pilot

- * July 2005- Jan 2006- 11 panels
- * R21, R03, R15, R01
- * Aug-Dec 2006- 38 SEPS
- * R03, R21, R01, R15, P01, SBIRs
- * Evaluation

Challenges

- Developing a culture of usage
- Less immersive than a face to face meeting
- Cognitive challenge & scalability
- Training
- * Technical challenges, integration, usability

Future Directions

- Scaling
 - No of panels
 - No of applications
 - Different Mechanisms
- Refining Protocols
- Greater Automation
- Integration
- Wider Adoption

Acknowledgments

- Project Management Team
 - McKay, Panniers, Srinivas, Blagaich, Chacko
- * Developers
 - Leo Wu, Sara Wu, Dipak Bhattacharyya, Yulia Shifrin,
- Reviewers
- CSR Staff
 - Bob Freund, Participating SRAs, IRG Chiefs, Electronics Committee, CSR DDs, CSR RTAs
- NIH Staff
 - Jack Jones, John Riston, Mikhail Gomon, Shawn Googins
- Executive Sponsors
 - Toni Scarpa, Cheryl Kitt